The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1493
April 25, 2016
View Complete Issue         Table of Contents 2019 
Cariprazine (Vraylar) for Schizophrenia and Bipolar I Disorder
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Cariprazine (Vraylar) for Schizophrenia and Bipolar I Disorder
April 25, 2016 (Issue: 1493)
The FDA has approved cariprazine (Vraylar – Actavis), an oral, once-daily, second-generation antipsychotic, for treatment of schizophrenia and for acute treatment of manic or mixed episodes associated with bipolar I disorder.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Cariprazine (Vraylar) for Schizophrenia and Bipolar I Disorder
Article code: 1493b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.